신속 진단 시장 : 제품 유형, 기술, 검체 유형, 용도, 최종사용자별 - 세계 시장 예측(2026-2032년)

The Rapid Diagnostics Market is projected to grow by USD 60.94 billion at a CAGR of 8.40% by 2032.

Rapid diagnostics are reshaping how health systems detect, triage, and manage infectious diseases, chronic conditions, and urgent-care decisions at the point of need. The market spans lateral flow assays, molecular point-of-care testing, immunoassays, rapid antigen tests, glucose and cardiac marker testing, pregnancy and fertility testing, and increasingly connected diagnostic platforms used in hospitals, retail clinics, pharmacies, laboratories, workplaces, community programs, and home-care settings.

Demand is supported by verified public-health priorities: the World Health Organization emphasizes faster testing for tuberculosis, HIV, malaria, hepatitis, influenza, COVID-19, sexually transmitted infections, and antimicrobial resistance, while the U.S. CDC and other national agencies continue to promote timely diagnosis as essential to outbreak control, appropriate therapy, and surveillance. The strongest opportunities in rapid diagnostics are emerging where point-of-care testing shortens time to treatment, reduces unnecessary antimicrobial use, expands access outside centralized laboratories, and improves digital reporting for public-health response.

Transformative Shifts in the Rapid Diagnostics Landscape

The rapid diagnostics landscape is moving from single-use, visually read tests toward connected, multiplexed, and data-enabled testing models. COVID-19 normalized at-home and point-of-care testing, accelerated regulatory familiarity with emergency-use pathways, and expanded consumer expectations for fast, convenient results. At the same time, the European Union In Vitro Diagnostic Regulation, evolving U.S. FDA oversight, and stronger quality requirements across major health systems are raising the bar for clinical evidence, manufacturing controls, labeling, usability, and post-market performance monitoring.

Another transformative shift is the convergence of decentralized care and laboratory-grade performance. Molecular point-of-care systems, digital readers, cloud connectivity, and sample-to-answer platforms are enabling faster decisions in emergency departments, primary care, pharmacies, urgent care centers, and remote settings. Procurement is increasingly influenced by total cost of care, interoperability, reimbursement clarity, supply-chain resilience, biosafety, and the ability to support public-health reporting while maintaining clinical accuracy across diverse patient populations.

Cumulative Impact of Artificial Intelligence on Rapid Diagnostics

Artificial intelligence is becoming a cumulative force across the rapid diagnostics value chain rather than a stand-alone feature. AI supports assay design, biomarker discovery, image-based interpretation, signal enhancement for low-concentration analytes, automated quality control, and workflow optimization. In settings such as digital microscopy, respiratory testing, sepsis risk stratification, antimicrobial stewardship, and connected home diagnostics, AI can help clinicians interpret rapid test results in clinical context and prioritize follow-up testing.

The measurable value of AI in rapid diagnostics depends on validated datasets, transparent performance metrics, cybersecurity, privacy protection, and regulatory-grade clinical evidence. Industry leaders are focusing on human-in-the-loop designs, bias evaluation across populations, device traceability, and integration with electronic health records. The highest-impact use cases will be those that improve sensitivity, reduce invalid tests, accelerate triage, detect operational quality issues, and convert rapid diagnostic results into actionable care pathways without increasing clinician burden.

Key Regional Insights Across Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

Asia-Pacific is one of the most dynamic rapid diagnostics regions because of large populations, high infectious-disease testing needs, expanding private healthcare, and government investment in domestic diagnostics capacity. China, India, Japan, South Korea, Australia, and ASEAN markets show rising demand for molecular point-of-care systems, rapid respiratory panels, women's health testing, diabetes monitoring, and chronic disease screening, supported by broader digital health adoption and growing laboratory networks.

North America remains a major innovation and commercialization hub, supported by advanced reimbursement structures, strong hospital networks, pharmacy-based testing, CLIA-waived testing pathways in the United States, and FDA-cleared platforms. Europe is shaped by the EU IVDR, which is increasing evidence requirements while supporting higher confidence in test performance, clinical documentation, and post-market surveillance. Latin America is gaining traction through decentralized testing for dengue, HIV, tuberculosis, sexually transmitted infections, and respiratory infections, although reimbursement, procurement capacity, and last-mile distribution remain uneven. The Middle East is investing in healthcare modernization, national screening programs, and digital health infrastructure, while Africa's rapid diagnostics adoption is strongly linked to malaria, HIV, tuberculosis, maternal health, outbreak preparedness, and donor-supported access initiatives coordinated with national health ministries.

Key Group Insights Covering ASEAN, GCC, European Union, BRICS, G7 & NATO

ASEAN markets are expanding rapid diagnostics through public-health programs, local distribution partnerships, and private-sector growth in Indonesia, Thailand, Vietnam, Malaysia, Singapore, and the Philippines. The region's priorities include dengue, tuberculosis, respiratory infections, maternal health, antimicrobial resistance monitoring, and affordable point-of-care testing in decentralized settings where laboratory access can vary between urban and rural populations.

The GCC is accelerating adoption through hospital modernization, national screening initiatives, medical tourism, and digital health infrastructure in Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman. The European Union is defined by IVDR compliance, cross-border quality expectations, and demand for clinically validated diagnostics that support antimicrobial stewardship and patient safety. BRICS countries represent high-volume opportunities in infectious disease, chronic disease, and domestic manufacturing, with policy emphasis on healthcare access and local production capacity. G7 markets lead in premium platforms, reimbursement evolution, companion testing integration, and clinical workflow adoption, while NATO countries emphasize preparedness, biosecurity, and resilient diagnostic supply chains for civilian and defense-related health readiness.

Key Country Insights for Rapid Diagnostics Adoption

The United States leads in rapid diagnostics innovation through FDA-cleared platforms, retail-clinic expansion, hospital point-of-care programs, CLIA-waived testing, and strong investment in molecular and digital testing. Canada emphasizes quality-assured diagnostics across provincial health systems, while Mexico and Brazil show growing demand for infectious-disease, women's health, dengue, respiratory illness, and chronic-care testing in mixed public-private systems that depend on distribution reach and procurement efficiency.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are prioritizing validated rapid testing that supports antimicrobial stewardship, respiratory disease management, emergency care, and decentralized healthcare under tighter regulatory expectations. Germany and France benefit from strong laboratory and hospital infrastructure, the United Kingdom emphasizes diagnostic access and care pathway efficiency, and Italy and Spain continue to expand rapid testing for respiratory, cardiovascular, and infectious disease use cases. Russia maintains demand for infectious-disease and hospital diagnostics despite trade, procurement, and supply-chain constraints.

China and India are major rapid diagnostics engines because of scale, domestic manufacturing, high testing volumes, and public-health needs spanning respiratory infections, tuberculosis, hepatitis, diabetes, and maternal health. Japan, South Korea, and Australia are advanced markets with strong quality standards, aging populations, established reimbursement structures, and adoption of connected diagnostic tools. Across these countries, rapid diagnostics adoption depends on clinical accuracy, affordability, reimbursement, distribution reliability, regulatory compliance, local service support, and integration with care pathways.

Actionable Recommendations for Rapid Diagnostics Industry Leaders

Industry leaders should prioritize clinically differentiated rapid diagnostics that prove measurable value in faster treatment, reduced hospital burden, antimicrobial stewardship, and improved access. Product portfolios should balance high-volume lateral flow tests with molecular point-of-care platforms, multiplex respiratory panels, cardiac markers, women's health diagnostics, diabetes monitoring, and digital readers that support traceability, quality control, and reporting.

Organizations should strengthen regulatory readiness for FDA, EU IVDR, and other national requirements by investing in real-world evidence, quality systems, usability studies, analytical validation, clinical validation, and post-market surveillance. Partnerships with pharmacies, primary-care networks, public-health agencies, laboratories, community programs, and telehealth providers can extend reach. Supply-chain localization, AI governance, cybersecurity, reimbursement evidence, and health-equity considerations should be treated as strategic priorities rather than operational afterthoughts.

Research Methodology for Rapid Diagnostics Analysis

This executive summary is based on secondary research and analytical triangulation from verified public-health, regulatory, clinical, and industry sources. Core references include guidance and datasets from the World Health Organization, U.S. CDC, U.S. FDA, European Commission, national health ministries, peer-reviewed journals, and recognized standards bodies. The analysis considers disease burden, regulatory policy, technology adoption, procurement patterns, reimbursement trends, digital health readiness, and healthcare infrastructure maturity.

Insights are synthesized using a top-down and bottom-up research approach that compares macro-level health priorities with product-level adoption indicators. Regional and country assessments consider demographic trends, infectious-disease prevalence, chronic disease needs, healthcare access, local manufacturing capacity, regulatory requirements, and decentralized care adoption. All claims are framed to avoid unsupported market estimates and focus on evidence-backed drivers, restraints, and opportunities in rapid diagnostics.

Conclusion: The Future of Rapid Diagnostics

Rapid diagnostics are becoming a strategic pillar of modern healthcare because they connect speed, access, and actionable clinical decision-making. The category is no longer defined only by test turnaround time; it is increasingly defined by accuracy, connectivity, usability, regulatory evidence, affordability, and the ability to improve patient outcomes across decentralized care settings.

The next phase of development will be led by validated molecular point-of-care systems, AI-enabled interpretation, multiplex testing, home diagnostics, and digitally connected platforms that support surveillance and care coordination. Organizations that combine scientific credibility, scalable manufacturing, regulatory excellence, resilient supply chains, and strong regional partnerships will be best positioned to advance the rapid diagnostics landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Rapid Diagnostics Market, by Product Type

• 7.1. Instruments
  • 7.1.1. Benchtop
  • 7.1.2. Portable
• 7.2. Reagents & Consumables
• 7.3. Test Kits

8. Rapid Diagnostics Market, by Technology

• 8.1. Immunoassay
• 8.2. Lateral Flow Assay
  • 8.2.1. Competitive
  • 8.2.2. Sandwich
• 8.3. Molecular Diagnostics
  • 8.3.1. Isothermal Amplification
  • 8.3.2. Pcr

9. Rapid Diagnostics Market, by Sample Type

• 9.1. Blood
  • 9.1.1. Whole Blood
  • 9.1.2. Serum
  • 9.1.3. Plasma
• 9.2. Urine
• 9.3. Saliva
• 9.4. Swab
  • 9.4.1. Nasal
  • 9.4.2. Nasopharyngeal
  • 9.4.3. Throat
• 9.5. Stool

10. Rapid Diagnostics Market, by Application

• 10.1. Cardiac Markers
  • 10.1.1. Creatine Kinase Mb
  • 10.1.2. Myoglobin
  • 10.1.3. Troponin
• 10.2. Diabetes
  • 10.2.1. Type 1 Diabetes
  • 10.2.2. Type 2 Diabetes
• 10.3. Infectious Diseases
  • 10.3.1. Bacterial Infections
  • 10.3.2. Parasitic Infections
  • 10.3.3. Viral Infections
• 10.4. Oncology

11. Rapid Diagnostics Market, by End User

• 11.1. Clinics
• 11.2. Home Care
• 11.3. Hospitals
• 11.4. Laboratories

12. Rapid Diagnostics Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Rapid Diagnostics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Rapid Diagnostics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Abingdon Health plc
• 16.3. Access Bio, Inc.
• 16.4. Becton, Dickinson and Company
• 16.5. Bio-Rad Laboratories, Inc.
• 16.6. BioGnost d.o.o.
• 16.7. bioMerieux SA
• 16.8. Chembio Diagnostics, Inc.
• 16.9. CTK Biotech, Inc.
• 16.10. Danaher Corporation
• 16.11. EKF Diagnostics Holdings plc
• 16.12. F. Hoffmann-La Roche Ltd.
• 16.13. GenBody Inc.
• 16.14. Guangzhou Wondfo Biotech Co., Ltd.
• 16.15. Hangzhou AllTest Biotech Co., Ltd.
• 16.16. Hardy Diagnostics
• 16.17. InBios International, Inc.
• 16.18. Lepu Medical Technology (Beijing) Co., Ltd.
• 16.19. Meridian Bioscience, Inc.
• 16.20. OraSure Technologies, Inc.
• 16.21. QuidelOrtho Corporation
• 16.22. SD Biosensor, Inc.
• 16.23. Sekisui Diagnostics, LLC
• 16.24. Siemens Healthineers AG
• 16.25. SureScreen Diagnostics Ltd
• 16.26. Thermo Fisher Scientific Inc.
• 16.27. Trinity Biotech plc